Candel Therapeutics to Share Insights at Upcoming Conference
NEEDHAM, Mass. - Candel Therapeutics, Inc. (CADL), a pioneering clinical-stage biopharmaceutical company dedicated to the development of innovative multimodal biological immunotherapies, has exciting news to share. The company's President and CEO, Paul Peter Tak, M.D., Ph.D., will grace the stage at the prestigious Canaccord Genuity 45th Annual Growth Conference, scheduled to occur soon. This major event will be held in Boston, aiming to connect industry leaders and investors with emerging biopharmaceutical advancements.
Event Details and Importance
Taking place on August 13, 2025, from 2:00 to 2:25 PM EST, Candel's presentation is expected to offer valuable insights into its innovative therapies and strategic vision. The webcast will be accessible following the event, allowing those unable to attend to catch the key highlights and discussions afterward.
What's New with Candel Therapeutics?
Candel is making headlines with its robust pipeline focused on empowering the body’s immune system to combat cancer effectively. The company has made significant strides, particularly with its lead product candidate, CAN-2409, which recently showed promising results in clinical trials targeting non-small cell lung cancer and pancreatic cancer, two of the most challenging cancers. Candel's focus on novel immunotherapies sets it apart in the crowded landscape of cancer treatment.
About CAN-2409 and Clinical Advancements
CAN-2409 stands out as a key component of Candel's adenovirus-based platform, which is uniquely designed to elicit an effective immune response against tumors. The product has successfully completed phase 2a clinical trials and is now advancing towards a pivotal phase 3 clinical trial for localized prostate cancer, backed by the FDA's Special Protocol Assessment.
FDA Designations and Their Significance
Moreover, the FDA has bestowed Regenerative Medicine Advanced Therapy (RMAT) Designation upon CAN-2409 for patients diagnosed with localized prostate cancer, underscoring the treatment's potential to offer significant patient benefits. This FDA designation reflects Candel's commitment to ensuring that its therapies meet high standards of safety and effectiveness.
Looking Ahead: Future Trials and Innovations
Notably, Candel is also progressing with CAN-3110, the leading candidate from its herpes simplex virus platform. Currently in a phase 1b clinical trial for recurrent high-grade glioma (rHGG), CAN-3110 has attracted attention for its innovative approach and has received the Fast Track Designation and Orphan Drug Designation from the FDA.
The enLIGHTEN Discovery Platform
Candel’s enLIGHTEN™ Discovery Platform leverages human biology and advanced analytics, marking a systematic approach to discovering new viral immunotherapies aimed at solid tumors. This innovative platform reflects Candel's strategic goal to position itself at the forefront of cancer treatment through cutting-edge scientific research.
Engaging with Investors and Key Stakeholders
The upcoming presentation at the Canaccord Conference is an opportunity for Candel to engage directly with a broader audience of investors and industry experts, showcasing its advances and strategic vision. The company aims to foster connections that can help propel its ambitious goals forward.
Connect with Candel Therapeutics
For those interested in learning more about Candel’s developments and future outlook, the website will host the replay of the presentation and additional information regarding its innovative platforms. Candel Therapeutics is committed to transparency and keeping stakeholders informed about its progress.
Frequently Asked Questions
What is Candel Therapeutics focused on?
Candel Therapeutics concentrates on developing multimodal biological immunotherapies to enhance the immune system's ability to fight various types of cancer.
What are the lead product candidates of Candel?
The lead product candidates include CAN-2409, targeting non-small cell lung cancer and localized prostate cancer, and CAN-3110, which is in trials for recurrent high-grade glioma.
What key designations has Candel received from the FDA?
Candel has received Regenerative Medicine Advanced Therapy Designation for CAN-2409 and is listed for Fast Track and Orphan Drug Designations for CAN-3110.
When is Candel's presentation at the Canaccord Genuity Conference?
Candel's presentation is scheduled for August 13, 2025, from 2:00 to 2:25 PM EST.
How can stakeholders keep updated with Candel's progress?
Stakeholders can visit www.candeltx.com for updates and to access recordings of key presentations.
